Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced ...

Cigna has announced a deal to cap client copays on popular GLP-1 weight loss drugs by Eli Lilly and Novo Nordisk at $200 per month, a sum that would count toward a patient's deductible.Currently ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

Cigna’s (NYSE:CI) health services arm ... Zepbound. The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200 under the new offering. Patients can save as much ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The GLP-1 drugs are currently only covered by half of The Cigna Group (NYSE:CI)’s clients. Customers who now provide coverage could save as much as 20%. The agreement comes after Lilly’s ...

Cigna is doubling ... also link patients to copay assistance programs for which they may be eligible. Evanko noted that one in ten Americans is set to be on a GLP-1 drug, but significant barriers ...